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 First Chlorpheniramine 2.8 ± 0.8 3 
  Diphenhydramine 1.7 ±1.0 2 
  Doxepin 2 na#
  Hydroxyzine 2.1 ±0.4 2
 
  
  Acrivastine 1.4 ±0.4 1 
  Ketotifen 3.6 ±1.6 na
  Cetirizine 1.0 ±0.5 1
  Loratadine/ 1.2 ±0.3
  Decarboethoxyloratadine*** 1.5 ±0.7 
2
  Ebastine/Carebastine*** 2.6 ±5.7 2 
  Fexofenadine 2.6 2 
  Mizolastine 1.5 1 
  Levocetirizine 0.8 ±0.5 1 
  Desloratadine 1-3 2 
  Rupatadine 0.75 2 
Comparative pharmacology of the 
H1 antihistamines
The United States National Library of Medicine 
defi nes the term pharmacokinetics as “the dynamic and 
kinetic mechanisms of exogenous chemical products, and 
the absorption, biotransformation, distribution, release, 
transport and elimination of drug substances according 
to their dosage and extent and rate of metabolism”.
Although the effi cacy of the different H
1
 antihistamines 
in the treatment of allergic patients is similar, even when 
comparing fi rst- and second-generation drugs, they are 
very different in terms of chemical structure, pharmacology 
and toxic potential. Consequently, knowledge of their 
pharmacokinetic and pharmacodynamic characteristics is 
important for the correct usage of such drugs, particularly 
in patients belonging to extreme age groups, pregnant 
women, or subjects with concomitant diseases.
The current requirements of the different drug agencies 
for authorizing the introduction of a new medication have 
led to the availability of much more information on the 
pharmacokinetic and pharmacodynamic characteristics of 
the second-generation antihistamines than on their fi rst-
generation predecessors. It seems that this consideration 
alone would advise the more widespread use of these 
more modern antihistamines – in contrast to the evidence 
supplied by the current sales statistics, which show fi rst-
generation antihistamines to be much more widely used.
Curiously, most of the pharmacological aspects of the 
new antihistamines are diffi cult to document, and remain 
largely unpublished – the only source for consultation 
being the summaries presented by the drug manufacturers 
at scientifi c congresses and meetings, or the famous 
 
Table 1. Absorption pharmacokinetics of some antihistamines.
     
 Generation Drug Tmax*(hours) Time to action (hours)**
* Time elapsed from administration via the oral route to maximum plasma concentration; ** Based on papule and erythema testing; *** Principal active metabolite. # na, 
not available. Modifi ed from reference 1.
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 First Chlorpheniramine Yes Possible na 
  Diphenhydramine Yes Possible Liver failure 
  Doxepin Yes Possible Liver failure 
  Hydroxyzine Yes Possible Liver failure 
 
  Acrivastine <50% Improbable nd 
  
Cetirizine <40% Improbable
 Liver and kidney 
     failure
  
Loratadine Yes Scantly improbable
 Liver and kidney 




 Liver and kidney 
     failure 
Keto, Erythro
 Second Fexofenadine <8% Yes (P glycoprotein) Kidney failure < or > bioavailability
 
  Mizolastine Yes Possible na
  
Levocetirizine <15% Improbable
 Liver and kidney 
     failure
  
Desloratadine Yes Improbable
 Liver and kidney 
     failure 
> bioavailability
  Rupatadine Yes Improbable Liver and kidney 
     failure 
“data on fi le” that are commonly found in the publicity 
literature of the different drug products. By consulting 
these data and the published reviews, the most important 
aspects in relation to the comparative pharmacology of 
the different antihistamines can be summarized in the 
sections below.
Absorption
Most antihistamines show good absorption when 
administered via the oral route, as is demonstrated by 
the fact that effective plasma concentrations are reached 
within three hours after dosing (Table 1) [1]. The good 
liposolubility of these molecules allows them to cross 
the cell membranes with ease, thereby facilitating their 
bioavailability.
Papule and erythema inhibition tests show that the 
great majority of antihistamines exert an effect upon this 
skin reaction mediated by histamine within 1-3 hours 
after oral dosing (Table 1) [2].
In some cases, concomitant administration with food 
can alter the plasma concentrations of these drugs. This is 
explained by the presence of active transport mechanisms 
across cell membranes – the best known of which 
are P glycoprotein and the organic anion transporter 
polypeptides. These proteins and polypeptides are located 
in the cell membrane, and function as active transport 
systems for other molecules showing affi nity for them. 
In some cases these transport systems act as important 
elements in drug absorption or clearance, while in other 
cases they allow tissue detoxifi cation, depending on 
whether they are located in intestinal cell membranes (in 
the former case) or at the blood-brain barrier (in the latter 
case).
Some antihistamines behave as substrates for these 
active transport systems, such as for example fexofenadine 
[3], while in other cases drug intestinal absorption is not 
seen to be affected – as is the case of desloratadine [4]. 
This may be interpreted as a negative aspect in that it 
can determine variations in antihistamine bioavailability 
when coadministered with other substrates of these same 
active transport systems. On the other hand, a positive 
aspect is represented by the fact that this mechanism is 
particularly important in relation to tissue detoxifi cation 
(i.e., clearance of toxic elements from the central nervous 
system), as will be seen below. For some antihistamines 
such as fexofenadine, variations in bioavailability 
have been documented associated with the combined 
administration of foods that serve as substrates for P 
Table 2. Metabolization pharmacokinetics of some antihistamines.






 Dose  
Comments
 
   metabolization  adjustment  
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glycoprotein – such as grapefruit or bitter orange juice 
[5] – as well as of drugs that have this same property, 
such as verapamil, probenecid or cimetidine [6].
Metabolization
Liver metabolization. Most antihistamines are 
metabolized and detoxifi ed within the liver by the group 
of enzymes belonging to the P450 cytochrome system. 
Only acrivastine, cetirizine, levocetirizine, desloratadine 
and fexofenadine [7] avoid this metabolic passage 
through the liver to an important degree – which makes 
them more predictable in terms of their desirable and 
undesirable effects. Cetirizine and levocetirizine are 
eliminated in urine, mainly in unaltered form, while 
fexofenadine is eliminated in stools following excretion 
by the biliary tract, without metabolic changes. The 
rest of antihistamines undergo liver transformation to 
metabolites that may or may not be active, and whose 
concentrations in plasma depend on the activity of the 
P450 enzyme system. This activity in turn is genetically 
determined. Some individuals show high intrinsic activity 
of this enzyme system, while others show lessened 
activity at baseline. These patients can be identifi ed by 
studying their expressed liver enzyme phenotype (e.g., 
CYP3A4 or CYP2D6). The activity of the liver enzyme 
complex can also be altered under special metabolic 
conditions such as infancy [8], advanced age [9], liver 
diseases [10], or by direct drug action upon the enzyme 
complex [11].
Drug interactions resulting in a decrease in plasma 
concentration of the drug may lessen its clinical effi cacy, 
as occurs when administering H
1
 antihistamines 
together with cytochrome P450 inducers such as the 
benzodiazepines [12]. In other cases an increase in 
plasma concentration of the antihistamine can result, 
and its adverse effects may thus increase as well. This 
occurs when coadministering the drug with other P450 
cytochrome substrates that competitively inhibit its 
metabolism, such as the macrolides, antifungals or 
calcium antagonists [13]. In these cases the safety margin 
of the antihistamine, i.e., the concentration range for 
which the incidence of adverse events is minimal, will be 
a very important consideration, since the plasma levels 
will be unpredictable. Thus, drug dose adjustment may 
prove necessary in all the above mentioned situations 
(Table 2).
Actions on target organs
Antihistamines are present in low concentrations in 
plasma, and such drug levels are generally not determined 
on a routine basis. From the pharmacokinetic perspective, 
the assay methods used have improved in recent years 
with the introduction of new techniques such as gas-
liquid chromatography and high performance liquid 
chromatography with mass spectrometry (HPLC-MS), 
which allow the detection of minimal concentrations in 
plasma and tissues, and the identifi cation of components 
and their metabolites. A large percentage of the circulating 
plasma antihistamine concentration is bound to plasma 
transporter proteins – fexofenadine and acrivastine 
being the molecules with the lowest percentage binding 
values (60-70% and 50%, respectively), since the rest of 
antihistamines are bound over 95% to plasma proteins. 
However, isolated pharmacokinetic study is of scant 
interest, and from the clinical point of view it is much 
more important to conduct pharmacodynamic studies that 
serve to defi ne aspects such as drug potency, mechanism 
of action, or toxicity.
Antihistamines act upon histamine receptors at the 
surface of the different cell types that express them. There 













 are extensively expressed by many 
cells within the body. The H
1
 receptor has been associated 
with many actions in relation to allergic infl ammation, 
such as rhinorrhea, smooth muscle contraction, and 
many forms of itching (pruritus). This is mediated by the 
transduction of extracellular signals through G protein and 
intracellular second messengers (inositol triphosphate, 
diacylglycerol, phospholipase D and A
2
, and increases in 
intracellular calcium concentration) [14]. Recently there 
have also been reports of NF-κB transcription factor 
activation by the H
1
 receptors, which would explain the 
antiinfl ammatory actions of antihistamines via this route 
– since the mentioned transcription factor is associated 
with actions such as the regulation of adhesion molecules, 




 receptors belong to the superfamily of G 
protein coupled receptors (GPCRs), and are encoded for 
by chromosome 3. The cloning and expression of these 
elements by recombinant cells has allowed advances 
in the study of these receptors that have changed our 
understanding of how they work. We now know that 
these receptors exhibit spontaneous activation of their 
intracellular messengers, requiring no binding by an 
agonist at surface level [15]. This spontaneous activity 
is referred to as constitutive activity and is attributable to 
the dynamic balance between two conformations of the 
receptor – activated (characterized by the production of 
intracellular second messengers) and inactive (no such 
intracellular signaling) [16]. This situation has led to 
reclassifi cation of the drugs that act upon these receptors, 
according to which of the two receptor conformations 
are stabilized as a result of their action. In this sense, if 
the ligand stabilizes the active receptor conformation, 
making it the predominant form, then the drug is referred 
to as an agonist, while if the inactive conformation is 
stabilized the drug is said to be a inverse agonist. In this 
way, histamine is an agonist, while the antihistamines are 
presently considered to be inverse agonists [17] instead 
of antagonists as previously believed (Figure 1). A neutral 
antagonist would block both receptor conformations on a 
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competitive basis, without altering the dynamic balance 
or baseline activation of the receptor. The clinical 
relevance of these fi ndings is still unclear, since no drug 
is presently available that acts as a neutral antagonist – 
though it would be interesting to develop different types 
of antihistamines according to their activity as potent 
inverse agonists or antagonists. The former would be of 
interest if the objective were to reduce intrinsic receptor 
activity, and the latter in the case of seeking continued 
intrinsic activity while preventing all agonist action 
[18].
The pharmacodynamic aspects relating to 
antihistamine actions upon the target organs are 
studied by means of experimental models, allowing the 
comparison of different antihistamines and prediction of 
their therapeutic actions.
Many models have been proposed with this objective 
in mind – the most widely accepted being the wheal and 
erythema inhibition test, and the allergic rhinitis model. 
New models have recently also been proposed, such 
as the receptor occupation model, which also will be 
addressed.
- In the wheal and erythema test, objective assessment 
is made of the intensity of the antihistaminic effect by 
measuring the inhibition of wheal and erythema formation 
induced by histamine injection into the skin, after oral 
dosing of the study drug. Practically all the antihistamines 
have been studied with this model, inducing signifi cant 
inhibition of wheal and erythema formation versus 
placebo, in an intense and constant manner over time. 
Figure 2 graphically refl ects one of the most interesting 
comparative studies made with this model [2], showing 
epinastine (not available in Spain) to be the fastest acting 
antihistamine according to this model, while cetirizine 
is defi ned as the most potent. The maximum effect on 
wheal and erythema formation is reached 5-8 hours after 
oral dosing, unlike the maximum plasma concentration, 
which is reached much earlier. However, in the case of 
most antihistamines, this effect is maintained for longer 
periods of time (though to different degrees depending 
Figure 1. The three different states in which the histamine receptor can be found. Case A: balance between the two 
conformations; B: predominance of the activated conformation via the action of an agonist; and C: predominance of the 
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on the drug involved) than the plasma levels – which 
decrease in the fi rst few hours after administration via 
the oral route [19,20]. Thus, fexofenadine and cetirizine 
maintain inhibitory action due to proportionality between 
the tissue and plasma drug concentrations strongly in 
favor of skin concentration, while other antihistamines 
such as loratadine or ebastine maintain a less potent 
though still considerable effect thanks to the suggested 
persistence in skin of their active metabolites.
The allergic rhinitis model is a clinical evaluation 
based on symptoms scoring in patients diagnosed with 
allergic rhinoconjunctivitis subjected to intranasal 
allergen or histamine provocation, followed by evaluation 
of the capacity of the previously administered study 
drug to inhibit the response to such provocation [21]. 
Such testing also must be performed on a randomized 
basis and with placebo control, in the same way as in 
wheal and erythema inhibition studies. In addition to 
the reduction in symptoms score, objective assessment 
of such inhibition can be established by determining 
nasal vascular permeability through the measurement 
of α macroglobulin (in the nasal secretions) [22]. In 
contrast to the differences detected when using the wheal 
and erythema test, few clinical differences are observed 
among the different antihistamines when this model is 
used. Practically all the new antihistamines present 
studies based on this test in their authorization registry 
applications presented to the different drug agencies 
– the conclusion being that their effi cacy is at least equal 
to that of some other already available and previously 
authorized antihistamine.
- The receptor occupation model arises from the 
paradoxical observation that antihistamines with a high in 
vitro affi nity (Ki) for the receptor and a very long plasma 
half-life (t1/2) induce less potent and briefer wheal and 
erythema inhibition than other antihistamines with a 
priori poorer pharmacokinetic performance. This model 
proposes receptor occupation (expressed as a percentage) 
determined 4 and 24 hours after oral administration as 
pharmacodynamic assessment criterion [23]. The greater 
receptor occupation, the better the pharmacodynamic 
behavior of the antihistamine. Such receptor occupation 
is calculated on the basis of receptor affi nity (Ki), the 
concentration of free antihistamine at the action site 
(which is close to the free plasma concentration of the 
antihistamine [C4h and C24h]), and the maximum 
percentage of binding sites for the antihistamine. The 
results obtained for the antihistamines desloratadine, 
fexofenadine and levocetirizine are reported in Table 3.
In relation to the pharmacodynamic particulars of any 
drug in general, it is also of interest to address the changes 
that occur as a result of continuous administration. Thus, no 
loss of peripheral antihistaminic effi cacy (tachyphylaxis) 
has been demonstrated following continuous daily dosing 
in any of the studies offering suffi cient methodological 
quality and involving follow-up periods of up to 12 
weeks, using the wheal and erythema inhibition test as 
measure of effi cacy. Similar results have been obtained in 
studies using the allergic rhinitis symptoms score system 
or urticarial lesions as effi cacy parameter [7].
The apparent tachyphylaxis reported in some studies 
in which the effi cacy criterion was action upon the lower 
Figure 2. Inhibition of skin 
wheal formation following 
the intradermal injection of 
histamine, and after prior oral 
administration of different 
antihistamines. Reproduced 
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airways or on the central nervous system may have been 
attributable to the specifi c study design involved, since the 
H
1
 receptors do not appear to differ in function according 
to their location [7]. The most important data in relation 
to the pharmacodynamics of several antihistamines are 
reported in Table 4.
An important aspect of the pharmacodynamics of a 
drug is the study of its distribution in the different body 
compartments. In pharmacokinetic terms, it is desirable 
for any drug to present the lowest distribution volume 
(Vd) compatible with the therapeutic objectives, i.e., 
interaction with the receptors at effective concentrations, 
avoiding distribution to those organs where the drug is 
either ineffective or toxic [24]. Most available drugs 
are extensively distributed throughout the body, as a 
result of their required liposolubility, which ensures 
good absorption via the oral route. This implies that the 
distribution of a drug is usually more extensive than 
 
Table 3. Receptor occupation for some antihistamines.
     
 Parameter Desloratadine Fexofenadine Levocetirizine
Dose (mg) 5 120 5
Binding to plasma proteins (%) 85  65 91
Free drug C
4h
 (nM) 1 174 28
Free drug C
24h
 (nM) 0.3 1.4 4
T
1/2
 (h) 27 14 8
Ki (nM) 0.4 10 3
Receptor occupation after 4 h (%) 71 95 90
Receptor occupation after 24 h (%) 43 12 57
Maximum wheal inhibition after 4 h (%) 34 100 100
Wheal inhibition after 24 h (%) 32 15 60
Maximum erythema inhibition after 4 h (%) 19 83 89
Erythema inhibition after 24 h (%) 41 35 74
Table 4. Wheal and erythema inhibition for some antihistamines.
    Wheal and erythema inhibition
    Single dose    Continuous administration  Other organs  
      in which
 Medication and
  
Time to action 
 
Duration of action Residual effect  Tachyphylaxis pharmacodynamic
 dose  (h) (h) after interruption during continuous  studies have 
    (days) not available administration been made
Acrivastine 8 mg 0.5  8 not available no Nose, eyes,
     bronchi 
Azelastine, nasal –  – – no Nose
Azelastine, oral 4 mga 4  12 7 no Bronchi
Cetirizine 10 mg 0.7 > 24 3 nob Nose, bronchi
Ebastine 10 mg 1 > 24 3 no Nose, eyes, 
      bronchi
Fexofenadine 60 mg 2  24 2 no Nose
Levocabastine, topical –  – – no Nose, eyes
Loratadine 10 mg 3  24 7 nob Nose, bronchi 
Mizolastine 10 mg 1  24 not available no –
Desloratadine 5 mg 2 > 24 7 no Nose, bronchi, 
skin
Levocetirizine 5 mg 1 > 24 3 no Nose, bronchi 
skin
a Not available in Spain; b Wheal and erythema inhibition data, published with high methodological quality.
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strictly required to ensure its therapeutic effect. A low 
distribution volume can be defi ned as the exchangeable 
water volume in the body that is freely and rapidly 
exchanged between the extracellular and cytosolic 
compartments. This volume has been calculated as 0.6 
l/kg [25]. Distribution volumes far below this value 
mean that the drug is unlikely to be freed from binding 
to its plasma transporter protein, thus remaining within 
the plasma compartment, while volumes far above the 
aforementioned value mean that the drug extensively 
binds to cell structures.
Figure 3 provides a schematic representation of 
action sites according to distribution volume. In general 
terms, three types of receptors can be differentiated: 
those located within the cell, such as CYT P450, which 
is located within the microsomes; those located external 
to and within the cell membranes, such as the potassium 
and calcium channels; and fi nally the so-called surface 
receptors, such as the 5-HT and H
1
 receptors. The H
1
 
receptors are widely distributed throughout the body, 
and are found in smooth muscle, endothelial and 
epithelial cells, eosinophils or neurons. A suffi ciently 
low distribution volume means that the intracellular 
receptors remain unaffected. Taking into account that the 
H
1
 receptors are easily accessible from the bloodstream, 
the H
1
 antihistamines do not require extensive tissue 
distribution for correct action. The advantages of a low 
distribution volume include minimum dose-dependent 
toxicity for cell and organs, minimum interindividual 
variations in therapeutic effect, a reduction in undesired 
drug interactions, and the absence of drug accumulation 
within the heart or liver. Table 5 reports the distribution 
volumes of a number of H
1
 antihistamines.
Lastly, from the pharmacodynamic perspective, it is 
important to mention that in addition to distribution of 
the drug throughout the different body compartments, the 
development of adverse effects is also conditioned by the 
presence of the previously commented cell detoxifi cation 
mechanisms, such as P glycoprotein. Particularly within 
the central nervous system, it has been demonstrated that 
P glycoprotein participates in the clearance from this 
body compartment of antihistamines such as cetirizine 
[26], carebastine, the active metabolite of ebastine [27], 
epinastine [28], fexofenadine [3], loratadine [29] and 
desloratadine [29]. In contrast, it does not contribute to 
clear fi rst-generation antihistamines or sedatives such as 
hydroxyzine, tripolidine or diphenhydramine [29]. This 
could help explain the clear difference in central nervous 
system side effects on the part of the new antihistamines. 
Accordingly, status as a P glycoprotein substrate appears 




 antihistamines are eliminated through 
the kidneys after metabolization to a lesser or greater 
extent. Biliary excretion is also possible, and is more 
Figure 3. Action sites identifi ed for 
the most common H
1
 antagonists. 









Endothelial cells of vessels, particularly the 





Mast cells and basophils, eosinophils, lymphocytes 
and polymorphonuclear cells (PMN).
Skin and connective tissue
Smooth muscle: vessels, bronchi, intestine, 





Potentially toxic locations. Adrenal glands, liver, 
heart, brain, retina.
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extensively applicable to fexofenadine and rupatadine 
– the former without metabolization and the latter after 
extensive metabolization. In special cases in which liver 
or kidney function is impaired, dose adjustment may 
prove necessary – as in elderly patients or subjects with 
kidney or liver failure.
Since an antihistamine in combination with a 
vasoconstrictor (pseudoephedrine) is very common 
prescription practice, and these drugs are mainly 
eliminated in urine, it is of interest to determine 
whether antihistamine excretion is affected when these 
drugs are administered in combination. This situation 
has been studied for loratadine – no effects upon the 
pharmacokinetics of the latter being observed when 
combined administration is carried out [30]. Likewise, 
the antihistamines can be eliminated in human milk 
– an aspect that has been studied for loratadine. In this 
context, 0.46% of the maternal therapeutic dose is seen 
to appear in milk [31].
Table 5 summarizes the comparative pharmacokinetics 
of the different antihistamines. Table 6 in turn reports 
the modifi cations in elimination half-life of some H
1
 
antihistamines, and the dose adjustment requirements in 
special patient populations.
Conclusions
Although no clinically relevant differences have been 
described among the different antihistamines in terms of 
effi cacy – even when contrasting the new drugs with the 
fi rst generation molecules – their evident differences in 
chemical structure and pharmacology (both kinetics and 
dynamics) cause the antihistamines to differ among each 
other from the potential toxicity perspective. As a result, 
detailed knowledge of these differentiating aspects is 
needed when deciding to prescribe one antihistamine or 
other for the treatment of allergic disorders – particularly 
when the patient belongs to a risk group, such as extreme 
ages, pregnancy, or in the presence of background disease 
affecting kidney or liver function.
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